Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
AlzChem adjusts the forecast for fiscal year 2020 due to COVID-19
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Trostberg, October 14, 2020 – Due to the continuing economic effects of the COVID-19 pandemic in individual target industries and regions, AlzChem Group AG adjusts its forecast for fiscal year 2020. The continued very positive development, especially for Bioselect® products, which are among other things an essential component of the COVID-19 test kits, cannot fully compensate for these effects.
Therefore, the company now expects to generate stable to slightly declining consolidated sales compared to the previous year (original forecast: slightly rising to sharply rising). A similar development can be expected for adjusted EBITDA (original forecast: stable to sharply rising).
Contact
Sabine Sieber
Head of Investor Relations & Communications
Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
About AlzChem
AlzChem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. AlzChem benefits in particular from the three very different global megatrends of sustainability, population growth and healthy aging. AlzChem products offer attractive solutions in a wide range of applications.
The company sees interesting growth prospects for itself above all in the fields of human and animal nutrition, pharmaceuticals, agriculture, fine chemicals, metallurgy and renewable energies. The broad product range includes, for example, dietary supplements, plant growth regulators and precursors for corona tests.
The company employs around 1,630 people at four production sites in Germany and Sweden, and at two sales companies in the USA and China.